Key result
Alamandine and its receptor MrgD are promising novel drug targets that may protect the kidney and heart through anti-hypertensive and vasodilatory actions.
Why the study?
Alamandine was recently identified as an endogenous MrgD ligand in the protective renin-angiotensin system, revealing previously unknown non-neuronal effects.
Alamandine and its receptor MrgD are part of the protective arm of the renin-angiotensin system and represent promising novel drug targets for cardiovascular and renal protection through anti-hypertensive actions.
Should not change practice yet; leaves open need for trials of alamandine/MrgD-targeted therapies.
Only a few years ago, alamandine was found to be a member of the protective arm of the renin-angiotensin system. It turned out to be an endogenous ligand of the G protein-coupled receptor MrgD. So far, MrgD had predominantly been studied in a neuronal context. The expression of the receptor in non-neuronal tissue showed hitherto unknown effects mediated by MrgD, most strikingly alamandine-induced vasodilation. Alamandine being a part of the non-classical renin-angiotensin system, a protective role of receptor activation seemed natural. This review summarizes the different effects of MrgD activation by alamandine in vasculature, in the central nervous system, and in organs as kidney and heart. Alamandine and MrgD are promising novel drug targets to protect the kidney and heart through anti-hypertensive actions.
No takes yet. Share an insight, caveat, or question.
Johanna Schleifenbaum (2019) conducted a review in Hypertension and cardiovascular diseases. Alamandine and MrgD receptor activation was evaluated. Alamandine and its receptor MrgD are promising novel drug targets that may protect the kidney and heart through anti-hypertensive and vasodilatory actions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: